Imeth

Methotrexate, the active ingredient in Imeth, is an antimetabolite presented as a subcutaneous formulation for injection use. It is employed to treat immune‑mediated diseases and certain malignancies in adult patients. GNH USA supplies Imeth as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Methotrexate is used in several immune‑mediated and oncologic conditions where it interferes with cell proliferation.

Rheumatoid arthritis: reduces joint inflammation and slows disease progression. Psoriasis: diminishes skin lesions and plaque formation. Certain cancers (e.g., leukemia, lymphoma): inhibits rapid tumor cell growth. Ectopic pregnancy: terminates trophoblastic tissue to avoid surgical intervention.

Methotrexate may cause a range of adverse reactions.

Common Side Effects: - Nausea or vomiting. - Fatigue or malaise. - Oral mucosal ulceration. - Elevated liver enzymes. - Mild leukopenia or thrombocytopenia.

Serious or Rare Side Effects: - Severe hepatotoxicity or fibrosis. - Pulmonary toxicity, including interstitial pneumonitis. - Life‑threatening infections due to immunosuppression. - Bone marrow failure or aplastic anemia. - Renal impairment or failure.

Methotrexate requires careful monitoring and specific safety measures.

Pregnancy: contraindicated (Category X) – avoid use in women who are pregnant or may become pregnant. Renal function: assess baseline creatinine and adjust dose if impairment is present. Liver function: monitor transaminases regularly; discontinue if severe elevation occurs. Infection risk: do not initiate therapy in patients with active infections. Concurrent immunosuppressants: use with caution and monitor blood counts. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several drug classes that may alter its safety or efficacy.

Major Interactions (Avoid): - Live vaccines: may cause severe infection. - NSAIDs: increase methotrexate toxicity. - Penicillamine: additive bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Sulfonamides: may enhance myelosuppression. - Proton pump inhibitors: may affect absorption. - Alcohol: can exacerbate hepatotoxicity.